Business Context and Reporting Period
This Form 8-K filing by Immudyne, Inc. (not Lifemd, Inc.) covers events occurring between January 29, 2018, and February 15, 2018. The report details a material definitive agreement involving the sale of the company's yeast beta glucan manufacturing business, significant changes in executive leadership, and board composition.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for a reporting period. Instead, it outlines the financial terms of a specific asset sale:
- Asset Sale: Sale of yeast beta glucan manufacturing assets and liabilities to an entity controlled by former CEO Mark McLaughlin.
- Revised Purchase Price: Amended on February 7, 2018, to include:
- 2,000,000 shares of Immudyne common stock.
- $190,000 cash payable on the Closing Date (February 12, 2018).
- $200,000 cash payable within 120 days of closing.
- Original Terms: Initially set at $850,000 total ($650,000 cash at closing, $200,000 deferred), but superseded by the amendment.
- Liquidity/Debt: The filing does not disclose the company's overall debt levels or liquidity position outside of the specific transaction payments.
Material Changes Versus Prior Period
The filing reports significant structural and operational changes:
- Asset Divestiture: The company sold its yeast beta glucan manufacturing business, shifting from a manufacturing model to a supply agreement model for its iNR Wellness products.
- Leadership Transition: Mark McLaughlin resigned as President, CEO, and Board member. Stefan Galluppi resigned from the Board.
- New Leadership: Justin Schreiber was appointed President and CEO.
- Board Representation: Mr. McLaughlin retains the right to appoint one director to the Board as long as he owns or controls over 9.9% of outstanding shares. He nominated Anthony Bruzzese, M.D., for this role.
Outlook, Risks, and Unusual Items
- Supply Agreement: Immudyne entered a one-year supply agreement with the buyer (Newco) to purchase all yeast beta glucan for its iNR Wellness products.
- Brand Usage: The company secured non-exclusive rights to use the name "Immudyne" for 60 days post-closing.
- Registration Rights: Immudyne agreed to include shares and options owned by Mr. McLaughlin in any future equity registration statements.
- Severance Waiver: Mr. McLaughlin waived all rights to severance upon resignation.
- Risk/Contingency: The assets were sold "as is" with no representations or warranties made by the company.
Investor Verification Checklist
- Verify the valuation of the 2,000,000 shares of common stock issued as part of the purchase price.
- Confirm the financial impact of transitioning from manufacturing to a third-party supply agreement for core products.
- Review the full text of the Asset Purchase Agreement (Exhibit 10.1) and First Amendment (Exhibit 10.2) for undisclosed covenants.
- Assess the strategic rationale for the CEO change and the continued board influence of the former CEO.
- Check subsequent filings for the actual closing of the transaction and the issuance of shares.